Meet the Elixir Team
Steve Cox (Director)
Steve founded Elixir in 2002. Since then, he has built a reputation as a trusted advisor, specialising in structuring individual financing solutions for early stage public and private life science companies. Under his stewardship, Elixir became the highest-ranked Independent research firm in biotech in the 2005 Extel Survey and has worked on a series of public and private fundraisings and advisory mandates.
Prior to founding Elixir, Steve was the Head of Biotech & Healthcare research at Commerzbank Securities where he coordinated the pan-European research team and sat on the Investment Commitment Committee for the Private Equity investment fund. Prior to Commerzbank Steve worked at UBS, where he was instrumental in Serono’s $2bn secondary financing and Genmab’s $230m IPO; HSBC, where he worked in the #1 ranked pharmaceuticals team and at Cazenove where he headed a team which was responsible for 16 IPOs in the sector raising over $640m in total for companies including Cambridge Antibody Technologies, Vernalis (previosly Vanguard Medica) and Celltech. Whilst at Cazenove, Steve also worked on the defense of Wellcome and Fisons against their respective bids from Glaxo and Rhone Poulenc.
Geoffrey Cox (Director)
Geoffrey F. Cox, Ph.D.has been Chairman, President and CEO of GTC Biotherapeutics since 2001. Under his stewardship, GTC became the first company to have a transgeni- protein therapeutic approved by a regulatory agency (the EMEA). Geoffrey has more than 30 years of pharmaceutical and biotechnology experience. In 1984, Geoffrey joined Genzyme Corporation in the U.K. and became Senior Vice President, Operations in the U.S. in 1988. Geoffrey later became Executive Vice President responsible for operations and the pharmaceutical, diagnostic and genetics business units of Genzyme.
Prior to joining Genzyme, Geoffrey was General Manager of U.K. manufacturing operations for Gist-Brocades. In 1997, Geoffrey became Chairman and CEO of Aronex Pharmaceuticals, Inc. and subsequently, in July 2001, became . Geoffrey is also a member of the Board of Directors of BIO and sits on their Emerging Companies Section and Healthcare Section Governing Body Committees. In 2007, Geoffrey was appointed Non-Executive Chairman of the Board of Directors for Nabi Biopharmaceuticals.
Rino Coladangelo (Director)
Dr Rino Coladangelo M.B.,B.S., M.R.C.P. is the Chief Executive officer of Medix Limited, a private UK-based provider of online scientific and commercial services both to Medical Practitioners and the Pharmaceutical industry. Rino is a senior physician with a clinical and management track record in both the NHS and private medicine. He has had extensive general medical experience as a Principal in a General practice for 17 years.
Rino trained at the Middlesex Hospital and held various senior management and clinical roles at North Hertfordshire NHS Trust including: Director of Primary Care Services, Managing Director, Clinical Services and ultimately as Chief Executive. He continues in part-time medical practice in London.